Stock Track | 3SBIO Soars 6.00% at Market Open on Positive ASCO Clinical Data and Pfizer Licensing Deal

Stock Track06-01

3SBIO's stock price soared 6.00% at market open on Monday, driven by positive clinical data presentations and a major licensing agreement.

The biopharmaceutical company presented impressive clinical data for its core pipeline asset SSGJ-707, a PD-1/VEGF bispecific antibody, at the ASCO Annual Meeting. In a Phase II study for advanced non-small cell lung cancer, SSGJ-707 monotherapy demonstrated a confirmed objective response rate of 67.6% with median progression-free survival of 12.4 months. For first-line endometrial cancer in combination with chemotherapy, confirmed response rates reached 85.7% and 80.0%, respectively.

Additionally, 3SBIO recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately $6.05 billion, including a $1.25 billion upfront payment, validating the asset's global commercial potential. The broader biotechnology sector also showed strength, providing additional positive momentum for 3SBIO's shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168285835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168285835","market":"sg","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 6.00% at Market Open on Positive ASCO Clinical Data and Pfizer Licensing Deal","media":"Stock Track","content":"<p>3SBIO's stock price soared 6.00% at market open on Monday, driven by positive clinical data presentations and a major licensing agreement.</p><p>The biopharmaceutical company presented impressive clinical data for its core pipeline asset SSGJ-707, a PD-1/VEGF bispecific antibody, at the ASCO Annual Meeting. In a Phase II study for advanced non-small cell lung cancer, SSGJ-707 monotherapy demonstrated a confirmed objective response rate of 67.6% with median progression-free survival of 12.4 months. For first-line endometrial cancer in combination with chemotherapy, confirmed response rates reached 85.7% and 80.0%, respectively.</p><p>Additionally, 3SBIO recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately $6.05 billion, including a $1.25 billion upfront payment, validating the asset's global commercial potential. The broader biotechnology sector also showed strength, providing additional positive momentum for 3SBIO's shares.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 6.00% at Market Open on Positive ASCO Clinical Data and Pfizer Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 6.00% at Market Open on Positive ASCO Clinical Data and Pfizer Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO's stock price soared 6.00% at market open on Monday, driven by positive clinical data presentations and a major licensing agreement.</p><p>The biopharmaceutical company presented impressive clinical data for its core pipeline asset SSGJ-707, a PD-1/VEGF bispecific antibody, at the ASCO Annual Meeting. In a Phase II study for advanced non-small cell lung cancer, SSGJ-707 monotherapy demonstrated a confirmed objective response rate of 67.6% with median progression-free survival of 12.4 months. For first-line endometrial cancer in combination with chemotherapy, confirmed response rates reached 85.7% and 80.0%, respectively.</p><p>Additionally, 3SBIO recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately $6.05 billion, including a $1.25 billion upfront payment, validating the asset's global commercial potential. The broader biotechnology sector also showed strength, providing additional positive momentum for 3SBIO's shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1168285835","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168285835","pubTimestamp":1780277839,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock price soared 6.00% at market open on Monday, driven by positive clinical data presentations and a major licensing agreement.The biopharmaceutical company presented impressive clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股追踪|ASCO临床数据利好及辉瑞授权交易三生制药开盘大涨6.00%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock price soared 6.00% at market open on Monday, driven by positive clinical data presentations and a major licensing agreement.The biopharmaceutical company presented impressive clinical data for its core pipeline asset SSGJ-707, a PD-1/VEGF bispecific antibody, at the ASCO Annual Meeting. In a Phase II study for advanced non-small cell lung cancer, SSGJ-707 monotherapy demonstrated a confirmed objective response rate of 67.6% with median progression-free survival of 12.4 months. For first-line endometrial cancer in combination with chemotherapy, confirmed response rates reached 85.7% and 80.0%, respectively.Additionally, 3SBIO recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately $6.05 billion, including a $1.25 billion upfront payment, validating the asset's global commercial potential. The broader biotechnology sector also showed strength, providing additional positive momentum for 3SBIO's shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168285835","isCrawlerRequest":true}